PHARMACOKINETICS OF HUMAN IMMUNOGLOBULIN G, 10%, ADMINISTERED INTRAVENOUSLY (IGIV), SUBCUTANEOUSLY (IGSC) OR FACILITATED SUBCUTANEOUSLY WITH RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES

被引：0
|
作者：
Wasserman, R. L. [1 ]
Melamed, I. [2 ]
Stein, M. [3 ]
Rubinstein, A. [4 ,5 ]
Puck, J. [6 ]
Gupta, S. [7 ]
Engl, W. [8 ]
Leibl, H. [8 ]
McCoy, B. [8 ]
Gelmont, D. [9 ]
Schiff, R. I. [9 ]
机构：
[1] DallasAllergyImmunology, Dallas, TX USA
[2] IMMUNOe, Centennial, CO USA
[3] Allergy Associates Palm Beaches, N Palm Beach, FL USA
[4] Albert Einstein Coll Med, Bronx, NY 10467 USA
[5] Montefiore Hosp, Bronx, NY USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
[7] Univ Calif Irvine, Irvine, CA USA
[8] Baxter BioSci, Vienna, Austria
[9] Baxter BioSci, Westlake Village, CA USA
来源：
JOURNAL OF CLINICAL IMMUNOLOGY | 2012年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [31] Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly
    Frifelt, JJ
    Tvedegaard, E
    Bruun, K
    Steffensen, G
    Cintin, C
    Breddam, M
    Dominguez, H
    Jorgensen, JD
    PERITONEAL DIALYSIS INTERNATIONAL, 1996, 16 (06): : 594 - 598
  • [32] TOLERABILITY AND SAFETY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS INFUSION OF HUMAN IMMUNE GLOBULIN G, 10%, IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES: A STUDY FROM NORTH AMERICA
    Kobayashi, R.
    Stein, M. R.
    Darter, A.
    Paris, K.
    Gupta, S.
    Testori, A.
    Engl, W.
    Leibl, H.
    Filhauer, K.
    Schiff, R. I.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2012, 109 (05) : A98 - A98
  • [33] Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability
    Wasserman, Richard L.
    Melamed, Isaac
    Kobrynski, Lisa
    Puck, Jennifer
    Gupta, Sudhir
    Doralt, Jennifer
    Sharkhawy, Marlies
    Engl, Werner
    Leibl, Heinz
    Gelmont, David
    Yel, Leman
    IMMUNOTHERAPY, 2016, 8 (10) : 1175 - 1185
  • [34] Tolerability and safety of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immune globulin G, 10%, in patients with primary immunodeficiencies: A study from North America
    Kobayashi, R.
    Stein, M.
    Darter, A.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Fielhauer, K.
    Schiff, R. I.
    ALLERGY AND ASTHMA PROCEEDINGS, 2013, 34 (03) : 298 - 298
  • [35] Long-Term Safety and Pharmacokinetics of Facilitated Subcutaneous Infusion of Immune Globulin (Human) 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients with Primary Immunodeficiency (PI)
    Melamed, Isaac
    Wasserman, Richard
    Stein, Mark
    Rubenstein, Arye
    Puck, Jennifer
    Gupta, Sudhir
    Engl, Werner
    Leibl, Heinz
    Gelmont, David
    Schiff, Richard
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 363 - 363
  • [36] EFFICACY, SAFETY AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS INFUSION OF IMMUNOGLOBULIN G IN ADULT PATIENTS WITH PRIMARY IMMUNODEFICIENCIES: PHASE 3 STUDY RESULTS
    Stein, Mark
    Wasserman, Richard L.
    Melamed, Isaac
    Rubinstein, Arye
    Puck, Jennifer
    Gupta, Sudhir
    Engl, Werner
    Leibl, Heinz
    McCoy, Barbara
    Yel, Leman
    Schiff, Richard I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (06) : 727 - 727
  • [37] TOLERABILITY AND EFFICACY OF FACILITATED-SUBCUTANEOUS INFUSION OF IMMUNE GLOBULIN (HUMAN), 10% AND RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS (PTS) WITH PRIMARY IMMUNODEFICIENCY DISEASE (PIDD)
    Stein, M.
    Wasserman, R. L.
    Melamed, I.
    Rubinstein, A.
    Engl, W.
    Leibl, H.
    McCoy, B.
    Gelmont, D.
    Schiff, R. I.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A95 - A95
  • [38] Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies
    Wasserman, Richard L.
    IMMUNOTHERAPY, 2014, 6 (05) : 553 - 567
  • [39] Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies
    Li, Zhaoyang
    Follman, Kristin
    Freshwater, Ed
    Engler, Frank
    Yel, Leman
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 128
  • [40] LONG-TERM EFFICACY OF RECOMBINANT HUMAN HYALURONIDASE (RHUPH20)-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN G (IGG) (IGHY; HYQVIA) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PID): INFECTION RATES OVER THE COURSE OF TREATMENT
    Wasserman, R. L.
    Stein, M.
    Kobrynski, L.
    Gupta, S.
    Grant, J.
    Rubinstein, A.
    Engl, W.
    Mccoy, B.
    Leibl, H.
    Yel, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (05) : A102 - A102
12345